Department of General Practice, Pingjiang New Town Community Health Service Center, Suzhou, China.
Department of General Practice, Runda Community Health Service Center, Suzhou, China.
Gynecol Endocrinol. 2021 Jul;37(7):591-599. doi: 10.1080/09513590.2021.1878139. Epub 2021 Jan 27.
We aimed to summarize the available data regarding the levels of leptin and adiponectin and the key modulators of endometriosis compared to the controls.
The electronic databases such as MEDLINE, Embase, Scopus, Cochrane Library, and Web of Science were searched up to October 2020. The circulating and peritoneal levels of leptin and circulating levels of adiponectin were included. We used the Cochrane's Q test and the statistic in this study. These tests' weighted mean difference (WMD) and 95% CIs were considered as the summary effect size. They were then pooled using a random-effects model with the DerSimonian-Laird method.
Twenty eligible articles (or 25 studies) with 2645 participants (1362 women with endometriosis and 1283 controls) were included. Pooled results showed that women with endometriosis had significantly higher leptin levels (WMD = 4.45 mg/ml, 95%CI = 2.42-6.49, < .01) and leptin/BMI ratio (WMD = 0.32 mg/ml, 95%CI = 0.23-0.42, < .001) than the controls, whereas adiponectin levels (WMD = -0.24 mg/ml, 95%CI = -4.27 to -0.01, = .038) were significantly lower. The pooled results also indicated significantly lower leptin levels in women with advanced-stage endometriosis (WMD = -8.07 mg/ml, 95%CI = -14.22 to -1.92, = .01) than in the early stage. It was found, however, that there were no significant differences in adiponectin levels of women with advanced-stage endometriosis (WMD = -0.16 mg/ml, 95%CI = -0.64 to 0.32, = .512) and the early-stage ones.
We showed that leptin levels and leptin/BMI ratio were significantly higher in women with endometriosis than the controls. Nonetheless, patients with endometriosis had significantly lower levels of adiponectin than the controls.
我们旨在总结与对照组相比，瘦素和脂联素水平以及子宫内膜异位症关键调节剂的可用数据。
截至 2020 年 10 月，我们检索了 MEDLINE、Embase、Scopus、Cochrane 图书馆和 Web of Science 等电子数据库。纳入了循环和腹膜中的瘦素和循环中的脂联素水平。我们在本研究中使用了 Cochrane 的 Q 检验和 统计量。这些检验的加权均数差（WMD）和 95%置信区间（CI）被视为汇总效应量。然后，我们使用具有 DerSimonian-Laird 方法的随机效应模型对它们进行汇总。
纳入了 20 项符合条件的文章（或 25 项研究），共有 2645 名参与者（1362 名患有子宫内膜异位症的女性和 1283 名对照组）。汇总结果显示，与对照组相比，患有子宫内膜异位症的女性的瘦素水平（WMD=4.45mg/ml，95%CI=2.42-6.49，<0.01）和瘦素/体重指数比值（WMD=0.32mg/ml，95%CI=0.23-0.42，<0.001）显著更高，而脂联素水平（WMD=-0.24mg/ml，95%CI=-4.27 至 -0.01，=0.038）显著更低。汇总结果还表明，晚期子宫内膜异位症患者的瘦素水平（WMD=-8.07mg/ml，95%CI=-14.22 至 -1.92，=0.01）显著低于早期。然而，我们发现晚期子宫内膜异位症患者（WMD=-0.16mg/ml，95%CI=-0.64 至 0.32，=0.512）和早期患者的脂联素水平没有显著差异。
我们表明，与对照组相比，子宫内膜异位症患者的瘦素水平和瘦素/体重指数比值显著更高。然而，子宫内膜异位症患者的脂联素水平显著低于对照组。
